Business Wire

deWiz Names Laszlo Varga as Chief Executive Officer

10.8.2021 12:49:00 EEST | Business Wire | Press release

Share

deWiz’s Board of Directors, including co-founders Christian Bergh and Markus Westerberg, have announced Laszlo Varga as deWiz’s new Chief Executive Officer, starting August 16. Varga will apply his extensive experience leading e-commerce businesses like Gents and EuroFlorist to deWiz’s go-to-market strategy in golf and help develop strategic extensions for deWiz’s technology with other sports and disciplines. As CEO, Varga will oversee the start-up’s transition to a comprehensive global strategy by aligning all aspects of deWiz businesses using his expertise across consumer products, digital marketing, and direct sales.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005498/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

deWiz is a revolutionary new wearable tech that delivers comprehensive golf swing analysis and unique instantaneous feedback via an electric pulse when a golfer's swing goes astray, which accelerates the learning process. (Photo: Business Wire)

Debuting this summer, deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback and high-precision swing data that accelerates golfers’ pace of learning and adds consistency. deWiz’s introduction to the golf and business world has already created a “buzz” with it being described by Forbes as looking to bring a “jolt to the golf training aid market ;” being profiled in Sweden’s leading financial media, Dagens Industri ; and being featured in Sport Techie’s Startups series .

“On behalf of my co-founder Markus and the deWiz board, I am thrilled to have Laszlo join our journey as we strive to help golfers improve faster with our science-backed technology as their competitive edge. As I continue as Chief Operations Officer for deWiz and as a board member, it’s a testament to how much we’ve accomplished since founding the company to have attracted somebody of Laszlo’s caliber and business acumen to lead our global strategy moving forward,” said Christian Bergh, co-founder and COO of deWiz.

“I’m super excited and proud to join the deWiz team. The product is truly revolutionary in helping athletes improve their performance by combining neural science with instant feedback and unmatched data capture. There is nothing else like deWiz in the golf market and the feedback we've gotten from the early users is overwhelmingly positive. With my experience and understanding of global e-commerce and direct sales to consumers, I hope to contribute to the accelerated growth and success of this awesome company that is on the front edge of innovation," said Laszlo Varga, CEO of deWiz.

Varga has a strong background in multi-national e-commerce and direct-to-consumer sales. Prior to joining deWiz, Laszlo was the CEO of Gents, a brand and online retailer for male grooming products. Before joining Gents, Varga was the CEO of Euroflorist, Europe’s largest flowers by wire company where he had a long and successful career, serving previously as Chief Operations Officer and Online Director, heading the online transition of sales. Varga’s entrepreneurial spirit and busines building skillset is also relied upon as a board member for Gents, CoolStuff and BoneProx. Varga is based in Malmö, Sweden, where he has spent the majority of his professional career after graduating from San Diego State University and competing at an elite level in kayaking.

DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz’s has been in development for more than five years and has attracted an impressive roster of ambassadors, including 2020 U.S. Open Champion Bryson DeChambeau, 10-time Major Champion Annika Sorenstam, 3-time Major Champion Vijay Singh, 2-time Major Champion Lydia Ko, 2016 Open Champion Henrik Stenson, 2019 Houston Open Champion Lanto Griffin and 2-time World Long Drive Champion Tim Burke. deWiz’s user-friendly app and wearable tech tracks the precise position of a golfer’s hands throughout their swing, providing a 3D analysis and delivering data showcasing Transition, Length of Backswing, Wedge Distance and Tempo. These unique deWiz data points provide measurable metrics that any avid golfer, teaching professional or world-class player can utilize to efficiently refine their swing. Currently for sale for 699 USD, deWiz is available across the United States, Canada, Europe, and South Korea (more markets opening regularly – visit the website for the latest updates). Please visit dewizgolf.com for more details on how to improve your swing faster or download the app to demo its features via Apple’s App Store or Google Play.

ABOUT deWiz
The deWiz golf training platform has been developed by former European Tour pro, PGA of Sweden certified instructor and motor learning author, Markus Westerberg, and entrepreneur and technology business leader Christian Bergh. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world elevate their enjoyment of the game through innovative technology that accelerates the pace of learning. deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback that is based on a scientific approach of breaking cycles within motor learning and propelling golfers to improve faster.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
David Schaefer, Chief Marketing Officer
David@dewizgolf.com, +46702877637

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye